- Conditions
- Jansen's Metaphyseal Chondrodysplasia
- Interventions
- PTH-IA
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 3 Years to 100 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- MT-251
- Drug
- Lead sponsor
- Mirador Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- SAR446523
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Celiac Disease
- Interventions
- TIMP-GLIA
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
- Interventions
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2033
- U.S. locations
- 39
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 32 more
- Conditions
- Overweight, Obesity
- Interventions
- NNC6989-0001, Placebo (NNC6989-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Gastrointestinal Cancer
- Interventions
- DB-1324
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Port Saint Lucie, Florida • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- surgical implantation
- Device
- Lead sponsor
- Neuralstem Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
- Interventions
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- BJ-001, Pembrolizumab
- Drug
- Lead sponsor
- BJ Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- mapatumumab, sorafenib
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 3 more
- Conditions
- Solid Tumors
- Interventions
- 609A
- Drug
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Cancer
- Interventions
- BMS-986258, Nivolumab, rHuPH20
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more
- Conditions
- Hematological Malignancies
- Interventions
- Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 2 more
- Conditions
- Healthy, Alzheimer Disease
- Interventions
- AL003, Saline Solution
- Biological · Other
- Lead sponsor
- Alector Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Delray Beach, Florida • Lady Lake, Florida • Orlando, Florida + 2 more
- Conditions
- Schizophrenia
- Interventions
- RBP-7000
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 42 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Willingboro, New Jersey
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- ONO-6414, Placebo
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Neoplasms
- Interventions
- Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
- Conditions
- Colorectal Cancer (Locally Advanced or Metastatic)
- Interventions
- SOT109
- Biological
- Lead sponsor
- SOTIO Biotech a.s.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Houston, Texas • Fairfax, Virginia
- Conditions
- Healthy
- Interventions
- Civamide
- Drug
- Lead sponsor
- Winston Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Influenza
- Interventions
- Placebo for VNT-101, VNT-101
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Bacterial Vaginosis, Fungal Vaginal Infections
- Interventions
- Cern Device
- Device
- Lead sponsor
- Cern Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Irvine, California • Orange, California • Santa Ana, California
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
- Interventions
- ABBV-400, Trifluridine/Tipiracil, Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
- Interventions
- IK-595
- Drug
- Lead sponsor
- Ikena Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- Duarte, California • Orange, California • Denver, Colorado + 12 more